AU2019231208B2 - Imidazodiazepinediones and methods of use thereof - Google Patents

Imidazodiazepinediones and methods of use thereof Download PDF

Info

Publication number
AU2019231208B2
AU2019231208B2 AU2019231208A AU2019231208A AU2019231208B2 AU 2019231208 B2 AU2019231208 B2 AU 2019231208B2 AU 2019231208 A AU2019231208 A AU 2019231208A AU 2019231208 A AU2019231208 A AU 2019231208A AU 2019231208 B2 AU2019231208 B2 AU 2019231208B2
Authority
AU
Australia
Prior art keywords
compound
optionally substituted
methyl
acceptable salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019231208A
Other languages
English (en)
Other versions
AU2019231208A1 (en
Inventor
Neil A. Castle
Matthew H. Daniels
Jean-christophe P. HARMANGE
Mark W. Ledeboer
Goran MALOJCIC
Thomas T. Tibbitts
Maolin Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GFB ABC LLC
Original Assignee
GFB ABC LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GFB ABC LLC filed Critical GFB ABC LLC
Publication of AU2019231208A1 publication Critical patent/AU2019231208A1/en
Application granted granted Critical
Publication of AU2019231208B2 publication Critical patent/AU2019231208B2/en
Assigned to GFB (ABC), LLC reassignment GFB (ABC), LLC Request for Assignment Assignors: GOLDFINCH BIO, INC.
Priority to AU2025202716A priority Critical patent/AU2025202716A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AU2019231208A 2018-03-05 2019-03-05 Imidazodiazepinediones and methods of use thereof Active AU2019231208B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025202716A AU2025202716A1 (en) 2018-03-05 2025-04-17 Imidazodiazepinediones and methods of use thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862638448P 2018-03-05 2018-03-05
US62/638,448 2018-03-05
PCT/US2019/020732 WO2019173327A1 (en) 2018-03-05 2019-03-05 Imidazodiazepinediones and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025202716A Division AU2025202716A1 (en) 2018-03-05 2025-04-17 Imidazodiazepinediones and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2019231208A1 AU2019231208A1 (en) 2020-09-17
AU2019231208B2 true AU2019231208B2 (en) 2025-01-23

Family

ID=67847465

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019231208A Active AU2019231208B2 (en) 2018-03-05 2019-03-05 Imidazodiazepinediones and methods of use thereof
AU2025202716A Pending AU2025202716A1 (en) 2018-03-05 2025-04-17 Imidazodiazepinediones and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025202716A Pending AU2025202716A1 (en) 2018-03-05 2025-04-17 Imidazodiazepinediones and methods of use thereof

Country Status (7)

Country Link
US (2) US11623930B2 (https=)
EP (1) EP3761989A4 (https=)
JP (2) JP7408557B2 (https=)
CN (2) CN118908961A (https=)
AU (2) AU2019231208B2 (https=)
CA (1) CA3093084A1 (https=)
WO (1) WO2019173327A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093084A1 (en) 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
JP2022551580A (ja) * 2019-10-04 2022-12-12 ゴールドフィンチ バイオ，インク． 巣状分節性糸球体硬化症および糖尿病性腎症のバイオマーカーに基づく処置
CN115927202A (zh) * 2023-01-10 2023-04-07 北京爱思益普生物科技股份有限公司 一种trpc5突变细胞株及其构建方法和应用
WO2024153028A1 (zh) * 2023-01-20 2024-07-25 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020460A1 (en) * 1993-03-11 1994-09-15 Smithkline Beecham Corporation Chemical compounds
TW201444844A (zh) * 2013-03-14 2014-12-01 Hydra Biosciences Inc 經取代之黃嘌呤及使用其之方法
CN107082782B (zh) 2013-03-15 2020-03-20 海德拉生物科学有限责任公司 取代的黄嘌呤及其使用方法
JP6667092B2 (ja) 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
DK3652176T3 (da) 2017-07-11 2022-01-17 Boehringer Ingelheim Int Substituerede xanthinderivater
CA3093084A1 (en) 2018-03-05 2019-09-12 Goldfinch Bio, Inc. Imidazodiazepinediones and methods of use thereof
EP3917940A1 (en) * 2019-01-30 2021-12-08 Rothamsted Research Ltd Cylodimer of dehydrosalicortin and derivatives thereof isolated from plant of the genus salix for use in cancer therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090163545A1 (en) * 2007-12-21 2009-06-25 University Of Rochester Method For Altering The Lifespan Of Eukaryotic Organisms

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMISTRY OF HETEROCYCLIC COMPOUNDS, 1998, vol. 34, no. 6, pages 719 - 722. *
JOURNAL OF HETEROCYCLIC CHEMISTRY, 1988, vol. 25, no. 4, pages 1179 - 1182. *
JOURNAL OF MEDICINAL CHEMISTRY, 1990, vol. 33, no. 10, pages 2818 - 2821. *

Also Published As

Publication number Publication date
JP2024037971A (ja) 2024-03-19
US20210087200A1 (en) 2021-03-25
US20230365575A1 (en) 2023-11-16
JP7408557B2 (ja) 2024-01-05
EP3761989A4 (en) 2021-11-24
US11623930B2 (en) 2023-04-11
JP7809096B2 (ja) 2026-01-30
AU2025202716A1 (en) 2025-05-08
CN112351781A (zh) 2021-02-09
US12466834B2 (en) 2025-11-11
JP2021516225A (ja) 2021-07-01
WO2019173327A1 (en) 2019-09-12
AU2019231208A1 (en) 2020-09-17
CN118908961A (zh) 2024-11-08
CN112351781B (zh) 2024-07-02
CA3093084A1 (en) 2019-09-12
EP3761989A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
AU2025202716A1 (en) Imidazodiazepinediones and methods of use thereof
AU2019344928B2 (en) Pyridazinones and methods of use thereof
AU2020277224B2 (en) Compounds for improving mRNA splicing
JP6585266B2 (ja) Ｈｓｐ９０の阻害による神経変性疾患の処置
Cohen et al. PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA
TWI776886B (zh) Sestrin-gator2交互作用之調節劑及其用途
EP3630774B1 (en) 5-5 fused rings as c5a inhibitors
KR101397554B1 (ko) 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
CA2906194A1 (en) Benzimidazole derivatives and uses thereof
EA031746B1 (ru) СТИМУЛЯТОРЫ sGC
KR20210117271A (ko) 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
WO2022090746A1 (en) Nmt inhibitors for treating senescence-associated diseases or disorders
CN114516856A (zh) 二氢异喹啉酮和异吲哚啉酮衍生物及其用途
WO2004031229A2 (en) P53 binding polypeptide
JP6669774B2 (ja) 筋萎縮の治療に有用な誘導体
EP2382205B1 (fr) Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique comme activateurs de hif
EP2904009B1 (en) Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein
KR102811806B1 (ko) 아다만탄 유도체 및 그 사용
KR102663372B1 (ko) 아다만틸메틸아민 유도체 및 그 의약으로서의 사용
JP2021507680A (ja) Ｅｆハンドカルシウム結合モチーフに由来するカルシウムキレート化ペプチド
JP2009510131A (ja) Ｓｕｍｏ化制御剤及びその用途
Blomberg et al. Molecular cloning and characterization of a novel gene upregulated early during postnatal rat lung development
KR19980702115A (ko) 자기면역 질환 및 동종이식 거부 치료를 위한 ｌｃｋ ｓｈ２ 특이성 화합물의 용도
CN116650667A (zh) 纳米脂质体包装的gp96 mRNA在制备治疗非酒精性脂肪肝的产品中的应用
Garzorz-Stark Die Rolle des Signal Transducer and Activator of Transcription 3 (STAT3) bei der axonalen Regeneration im zentralen Nervensystem

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GFB (ABC), LLC

Free format text: FORMER APPLICANT(S): GOLDFINCH BIO, INC.

FGA Letters patent sealed or granted (standard patent)